Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06328374
Other study ID # 240420
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source Vanderbilt University Medical Center
Contact Cara Donohue
Phone 615-852-5085
Email cara.donohue@vumc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research study is investigating whether people with Alzheimer's disease experience more changes to voice and swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe Alzheimer's Disease is high (85-93%) and voice is also often negatively impacted by Alzheimer's disease. The overall objective of this study is to evaluate the voice and swallowing function of adults with and without Alzheimer's disease. The investigators will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of voice and swallowing impairments on the primary caregivers of those with Alzheimer's Disease. Healthy adults and individuals with Alzheimer's disease will: - undergo tests of cough, voice, and swallow function - undergo tests of grip and tongue strength - complete questionnaires Caregivers of individuals with Alzheimer's disease will also complete questionnaires.


Description:

This study will involve one in-person research visit that will last approximately 1-1.5 hours and will consist of a screening, cough testing, swallow function testing, vocal function testing, assessments of hand grip and tongue strength, and completion of questionnaires. Caregivers of those with Alzheimer's disease will also complete questionnaires at this initial visit. Following the first research evaluation visit, individuals will be contacted via email or by phone annually for two consecutive years to complete the same questionnaires completed at the initial visit.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date December 2026
Est. primary completion date March 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 100 Years
Eligibility Healthy Adult Cohort Inclusion Criteria 1. healthy community dwelling adult (60-100 years old) 2. no prior history of neurological diseases 3. no prior history of respiratory diseases 4. no prior history of head and neck surgery/head and neck cancer/radiation to head and neck region 5. no prior history of swallowing difficulties 6. no prior history of gastroesophageal diseases/impairments 7. absence of vocal fold lesions or paresis/paralysis 8. no recent intubation (=3 weeks) 9. score =26 on the Montreal Cognitive Assessment (MOCA) or the telephone version of the MOCA (t-MOCA) Exclusion Criteria 1. individual <60 years old, >100 years old 2. history of neurological disease 3. history of respiratory disease 4. history of head and neck surgery/head and neck cancer/radiation to head and neck region 5. history of swallowing difficulties 6. history of gastroesophageal diseases/impairments 7. presence of vocal fold lesions or paresis/paralysis 8. recent intubation (<3 weeks) 9. score <26 on the Montreal Cognitive Assessment (MOCA) or the telephone version of the MOCA (t-MOCA) AD Cohort Inclusion Criteria 1. between 60-100 years old 2. diagnosis of AD by neurologist 3. consuming some form of oral intake 4. able to follow basic directions Exclusion Criteria 1. individual <60 years old, >100 years old 2. diagnosis of another type of dementia 3. not consuming any oral intake 4. unable to follow basic directions Caregivers of Individuals with AD Cohort Inclusion Criteria 1. primary caregiver of an individual with AD 2. willing to complete questionnaires/semi-structured interview Exclusion Criteria 1. not the primary caregiver of an individual with AD 2. unwilling to complete questionnaires/semi-structured interview

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Swallowing safety The penetration aspiration scale is a validated 8-point ordinal rating scale that measures the depth of airway invasion and the patient's response during swallowing. Scores range from 1 to 8 with a score of 1 indicating a safe swallow (best score) and 8 indicating silent aspiration (worst score). During baseline visit at time of enrollment.
Primary Voluntary cough peak expiratory flow A measure of cough strength During baseline visit at time of enrollment.
Primary Vocal fold bowing index Vocal fold bowing will be completed as described by Bloch and Behrman. During baseline visit at time of enrollment.
Secondary Swallowing and Eating Related Fatigue Questionnaire (SERF) Scores on the SERF range 0-48 with higher scores indicating greater impairment. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Swallowing Related Quality of Life Questionnaire (SWAL-QOL) Scores on the SWAL-QOL range from 0-100 with lower scores indicating greater impairment. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Voice Handicap Index (VHI) The VHI contains 30 questions, and scores range from 0-120, with higher scores indicating greater perceived voice handicap. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Aging Voice Index (AVI) he AVI consists of 23 questions, with scores ranging from 0-92. Higher scores indicate a greater effect of dysphonia on quality of life. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Grip Strength Grip strength be used to quantify clinical frailty using a digital hand dynamometer. During baseline visit at time of enrollment.
Secondary Tongue strength Tongue strength will be assessed using the Iowa Oral Pressure Instrument (IOPI). During baseline visit at time of enrollment.
Secondary Clinical frailty scale The clinical frailty scale (scores 1-9) will be used to classify frailty with higher scores indicating greater impairment. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Caregiver Analysis of Reported Experiences with Swallowing Disorders (CARES) Questionnaire Scores on the CARES range from 0-26 with higher scores indicating greater caregiver burden. During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
Secondary Caregiver Self-Assessment Questionnaire Scores range from 0-16 with higher scores indicating greater caregiver burden During baseline visit at time of enrollment, 1 year after baseline visit, 2 years after baseline visit.
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A